<DOC>
	<DOCNO>NCT02990845</DOCNO>
	<brief_summary>This open-label , single-arm , multicenter , pilot study pembrolizumab , exemestane , leuprolide subject resistant front-line hormonal therapy inoperable locally advanced metastatic hormonal receptor positive ( HR+ ) / Human epidermal growth factor receptor 2 ( HER2 ) negative breast cancer . All patient include final tolerability preliminary efficacy analysis . The efficacy objectives include PFS , overall response rate ( ORR ) , clinical benefit rate ( CBR ) , duration response ( DOR ) . Adverse effect record accord CTCAE v4.0 .</brief_summary>
	<brief_title>Pembrolizumab Exemestane/ Leuprolide Premenopausal HR+/ HER2- Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1 . Be female adult age 20yearold time inform consent . 2 . Have histologically confirm ER positive ( defined ≥1 % ) and/ PR positive ( defined ≥1 % ) breast cancer . 3 . Have histologically confirm HER2negative breast cancer define IHC ≤ 2+ , and/or FISH negative . 4 . Have radiological objective evidence inoperable locally advanced metastatic breast cancer . 5 . Be premenopausal perimenopausal . Premenopausal perimenopausal status define : Last menstrual period within last 12 month OR With plasma estradiol ≥10pg/ml FSH ≤40IU/L 6 . Be resistant front line hormonal therapy , define one follow criterion : Have become inoperable locally advanced metastatic disease within one year adjuvant hormonal therapy . Fail least 2 line prior hormonal therapy locally advance metastatic breast cancer . Have history disease progress within 6 month 1st line hormone therapy locally advance metastatic disease . 7 . Prior exemestane usage allow , patient number limited ≤10 patient . 8 . Have archival primary tumor specimen diagnosis . 9 . Have metastatic tumor specimen enrollment . 10 . Have measurable disease per RECIST 1.1 nonmeasurable lytic mixed ( lytic + blastic ) bone lesion absence measurable disease . 11 . Have ECOG performance status 0 1 assess within 10 day treatment initiation . 12 . Have adequate bone marrow organ function . 13 . For woman childbearing potential must negative serum betahCG urine pregnancy test obtain within 3 day start treatment . 14 . Female subject childbearing potential must willing use adequate method contraception outline Section Contraception , course study 120 day last dose study medication . 15 . Be able comply study procedure sign inform consent . 1 . Is currently participate investigational agent study . 2 . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 1 week prior first dose study treatment . Physiological steroid replacement allow . 3 . Has chemotherapy within 2 week prior first dose study treatment recover side effect ( i.e . Grade 1 baseline ) except alopecia relate prior therapy . 4 . Is hepatitis B C carrier . 5 . Has concurrent malignancy nonmelanoma skin cancer . 6 . Is able undergo metastatic tumor biopsy . 7 . Has active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid immunosuppressive drug ) . Note : Replacement therapy ( i.e . thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment . 8 . Has history ( noninfectious ) pneumonitis require steroid , current pneumonitis . 9 . Has active infection require systemic therapy . 10 . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . 11 . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . 12 . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 agent agent direct another coinhibitory Tcell receptor ( e.g . CTLA4 , OX40 , CD137 ) previously participate Merck pembrolizumab clinical trial . 13 . Has receive livevirus vaccination within 30 day plan treatment start . Seasonal flu vaccine contain live virus permit . 14 . Is lactate , pregnant , unwilling employ birth control method study .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>